← Back to Screener
Cellectis S.A. American Depositary Shares (CLLS)
Price$3.06
Value ScoreB
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-48.40%
Price vs S&P 500 (4W)-21.84%
VGM Score53.96
Market Capitalization$194.56M
All Metrics
P/CF (Annual)10.79x
Book Value / Share (Quarterly)$1.05
P/TBV (Annual)4.58x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)45.72%
Cash Flow / Share (Quarterly)$-0.59
Price vs S&P 500 (YTD)-44.42%
Gross Margin (TTM)34.83%
Net Profit Margin (TTM)-68.19%
EPS (TTM)$-0.85
10-Day Avg Trading Volume0.30M
EPS Excl Extra (TTM)$-0.85
Revenue Growth (5Y)5.97%
EPS (Annual)$-0.67
ROI (Annual)-36.47%
Gross Margin (Annual)43.61%
Net Profit Margin (5Y Avg)-393.48%
Cash / Share (Quarterly)$2.88
Revenue Growth QoQ (YoY)-37.25%
ROA (Last FY)-20.82%
Revenue Growth TTM (YoY)56.76%
EBITD / Share (TTM)$-0.34
ROE (5Y Avg)-75.60%
Operating Margin (TTM)-40.39%
Cash Flow / Share (Annual)$-0.59
P/B Ratio2.95x
P/B Ratio (Quarterly)4.55x
Net Income / Employee (Annual)$-295,200
EV / Revenue (TTM)2.11x
Net Interest Coverage (TTM)-0.95x
ROA (TTM)-24.57%
EPS Incl Extra (Annual)$-0.67
Current Ratio (Annual)1.62x
Quick Ratio (Quarterly)1.61x
3-Month Avg Trading Volume0.28M
52-Week Price Return104.02%
EV / Free Cash Flow (Annual)8.19x
Revenue / Employee (TTM)$542,800
Tangible BV / Share (Quarterly)$1.04
P/S Ratio (Annual)2.82x
Asset Turnover (Annual)0.25x
52-Week High$4.84
Operating Margin (5Y Avg)-367.53%
EPS Excl Extra (Annual)$-0.67
CapEx CAGR (5Y)-41.81%
Tangible BV CAGR (5Y)-22.75%
26-Week Price Return-40.47%
Quick Ratio (Annual)1.61x
13-Week Price Return-20.24%
Total Debt / Equity (Annual)1.44x
Current Ratio (Quarterly)1.62x
Enterprise Value$272.10M
Revenue / Share Growth (5Y)-10.75%
Asset Turnover (TTM)0.37x
Book Value / Share Growth (5Y)-30.44%
Revenue / Employee (Annual)$347,600
Inventory Turnover (Annual)82.27x
Pretax Margin (Annual)-85.46%
Cash / Share (Annual)$2.88
3-Month Return Std Dev65.95%
Gross Margin (5Y Avg)-84.99%
Net Income / Employee (TTM)$-370,200
ROE (Last FY)-89.05%
Net Interest Coverage (Annual)-0.85x
EPS Basic Excl Extra (Annual)$-0.67
P/FCF (TTM)4.56x
Receivables Turnover (TTM)12.20x
Total Debt / Equity (Quarterly)1.44x
EPS Incl Extra (TTM)$-0.85
Receivables Turnover (Annual)7.54x
ROI (TTM)-43.24%
P/S Ratio (TTM)1.80x
Pretax Margin (5Y Avg)-412.20%
Revenue / Share (Annual)$0.79
Tangible BV / Share (Annual)$1.04
Price vs S&P 500 (52W)79.65%
Year-to-Date Return-37.07%
5-Day Price Return-12.76%
EPS Normalized (Annual)$-0.67
ROA (5Y Avg)-26.23%
Net Profit Margin (Annual)-84.92%
Month-to-Date Return-14.17%
Cash Flow / Share (TTM)$-0.66
EBITD / Share (Annual)$-0.13
Operating Margin (Annual)-41.56%
LT Debt / Equity (Annual)0.98x
ROI (5Y Avg)-39.44%
LT Debt / Equity (Quarterly)0.98x
EPS Basic Excl Extra (TTM)$-0.85
P/TBV (Quarterly)4.58x
P/B Ratio (Annual)4.55x
Inventory Turnover (TTM)93.83x
Pretax Margin (TTM)-68.50%
Book Value / Share (Annual)$1.05
Price vs S&P 500 (13W)-28.50%
Beta0.51x
P/FCF (Annual)11.71x
Revenue / Share (TTM)$1.24
ROE (TTM)-87.43%
52-Week Low$1.23
vGradeB
gGradeC
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.23
4.23
4.23
4.23
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CLLSCellectis S.A. American Depositary Shares | B | C | C | $3.06 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Cellectis SA is a clinical-stage biotechnology company developing gene-editing treatments for cancer and other diseases. The company's pipeline includes allogeneic CAR-T cell therapies for immuno-oncology and gene-edited stem cell products for other therapeutic areas. Its proprietary technology platform creates off-the-shelf cellular therapies with the potential for improved clinical outcomes and broader patient access.